BPG is committed to discovery and dissemination of knowledge
Minireviews
Copyright: ©Author(s) 2026.
World J Gastroenterol. Dec 14, 2026; 32(46): 123234
Published online Dec 14, 2026. doi: 10.3748/wjg.123234
Table 2 Summary of multi-level clinical interventions for intestinal failure in critically ill patients
Intervention level
Primary strategy
Key measures
Primary clinical outcomes
Effect size/results
Ref.
MicrobiotaASPOptimize selection, shorten courses, reduce broad-spectrum coverageBroad-spectrum antibiotic use rate, AGI incidenceUse rate ↓ 20%-30%; AGI incidence ↓ 15%-25%[37]
MicrobiotaMicrobial reconstitution (probiotics/synbiotics)Probiotic/synbiotic supplementationAntibiotic-associated diarrhea incidenceRR = 0.70-0.80[49]
MicrobiotaMicrobial reconstitution (FMT)FMTCDAD success rate, 30-day mortalitySuccess rate 80%-90%; mortality significantly reduced[42,43]
MetabolicNutritional support and SCFA restorationFiber-enriched enteral nutritionAGI severity, butyrate-producing bacteria abundanceOR = 0.82-0.86[46]
Metabolic/barrierEarly enteral nutritionInitiated within 48 hoursBloodstream infection rate, ICU length of stayOR = 0.73 (95%CI: 0.57-0.93)[52]
BarrierBarrier protectionGlutamine supplementationIntestinal permeabilityImproved in high-dose, short-course subgroup; no significant benefit otherwise[55]
InflammatoryImmunomodulation and anti-inflammatory therapyLow-dose corticosteroids, etcMortality in sepsisRR = 0.87 (95%CI: 0.81-0.93)[56]
SystemicOrgan support (high-quality evidence)Hemodynamic management, mechanical ventilationShort-term prognosis, acute-phase mortalityStandardized implementation improves short-term outcomes; does not address upstream dysbiosis[57]
SystemicCRRT (moderate-quality evidence)Continuous renal replacement therapyCytokine clearance, fluid balanceSome attenuation of circulating mediators; effect on gut microbiota unproven[57]


Write to the Help Desk